Doug Williams ups the ante at Co­di­ak Bio to $168.5M in a dri­ve to first hu­man study

When Doug Williams ex­it­ed his role as R&D chief at Bio­gen a cou­ple of years ago to run his own start­up, he made the leap based on the promise that some of the ven­ture play­ers in biotech were buy­ing in­to a whole new ap­proach to com­pa­ny cre­ation.

Shoe­string bud­gets were be­ing re­placed with com­pa­ny launch plans that dwarfed the old VC mod­el. And a tra­di­tion­al fo­cus on one or two as­sets shift­ed to a com­mit­ment to pricey pipeline con­struc­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.